In this Review, the authors provide an overview of circulating tumour DNA and circulating tumour cells as potential biomarkers to provide therapeutic guidance and optimize disease surveillance in bladder cancer. Challenges associated with these biomarkers and future perspectives for clinical implementation are also discussed.
- Sia V. Lindskrog
- Trine Strandgaard
- Lars Dyrskjøt